Search

everythinglearnresearchcommunity

for

Search:↓

The type of PCOS a woman has doesn't strongly predict her skin or metabolic symptoms; obesity is a more important factor.

Using anabolic-androgenic steroids can harm men's reproductive health and increase the risk of heart problems and death.

Ethnicity affects how polycystic ovary syndrome shows up in women, with white women having higher metabolic risks but less diabetes, and South Asian women showing more androgenic symptoms and being younger at presentation.

Anabolic-androgenic steroids harm male hormone levels, sperm, metabolism, and can cause acne, hair loss, and breast growth.

Many women with PCOS have abnormal cholesterol levels, needing careful management.

Progestogens are essential in menopausal hormone therapy to prevent uterine cancer and must be chosen carefully based on individual needs.

Autoimmune markers may help diagnose and manage PCOS.

Choosing the right estroprogestin is crucial for effectively managing PCOS symptoms.

Women with PCOS are more likely to experience sexual dysfunction, but lifestyle changes and weight loss can improve sexual function.

Teriflunomide is effective and generally safe for treating relapsing-remitting multiple sclerosis.

Testosterone therapy can improve sexual function in women but long-term safety is unclear.

The birth control combination of ethinylestradiol and drospirenone helps treat symptoms of polycystic ovary syndrome.

Medications for PCOS don't seem to raise heart disease risk.

Women with PCOS face higher risks of diabetes and heart disease, and these risks increase with obesity.

Premature hair greying may indicate a higher risk of metabolic problems.

Hair loss may indicate higher heart risk and metabolic issues.

Aleglitazar and its major metabolite are safe enough to proceed to Phase 3 clinical trials.

Obese and lean women with PCOS have different symptoms and need different treatments.

Lower SHBG levels may increase the risk of PCOS.

Some skin diseases may indicate a higher risk of metabolic syndrome and related health issues.

Higher basal metabolic rate increases the risk of non-alcoholic fatty liver disease, especially in Chinese people, and may require tailored management.

Changing the diagnosis criteria for PCOS might miss women at risk for related health issues.

Osteoporotic postmenopausal Sudanese women have a high risk of cardiovascular disease.

Mild thyroid issues don't affect the metabolism and hormones of women with PCOS.

Some skin conditions may indicate metabolic syndrome, which could help with early detection and management of related health issues.

Melatonin improved mental health and metabolism in women with PCOS.

Obese women with PCOS are more likely to have fatty liver disease.

Genetic counselors should be culturally skilled and aware of transgender patients' unique health risks and needs.

Metformin improves menstrual cycles and hormone levels in women with PCOS, mostly within the first 6 months.

Anovulatory PCOS patients are younger with longer cycles and higher blood pressure and hormone levels.